STOK Phase III Dravet and sustained seizure reduction support milestones
STOK says a phase III Dravet syndrome readout is expected within 12 months and progress continues in ADOA trials. Zorevunersen reports sustained 75% seizure reduction plus functional gains, with OLE data supporting long-term efficacy.